Skip to main content
2025 AABB Annual Meeting Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Event Icons
Assessor Sessions
Assessor Sessions
Committee Meetings
Committee Meetings
Foundation Events
Foundation Events
Networking Events
Networking Events
Oral Abstracts
Oral Abstracts
CABP Eligible
CABP Eligible

Leadership - Operations

(P-LP-1) Assessing Production Costs for Pathogen Reduced Cryoprecipitated Fibrinogen Complex and Cryoprecipitated Antihemophilic Factor – a Blood Center Budget Impact Model

Sunday, October 26, 2025
12:00 PM - 1:00 PM  PT

    Presenting Author(s)

  • VC

    Vera Chrebtow

    Cerus Corporation, Concord, CA, USA, United States

Background/Case Studies: Cryoprecipitated Antihemophilic Factor (Cryo AHF) and Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT® Fibrinogen Complex, IFC) are used to supplement fibrinogen in patients with hypofibrinogenemia. Both are produced from pooled whole blood derived (WBD) plasma but differ in the manufacturing process which ultimately impacts product availability as well as production costs. Manufactured from Amotosalen/UVA treated plasma, IFC provides a fibrinogen source with a 5-day post-thaw shelf-life as well as reduced transfusion-transmission infection risk. Here we present a model that compares the financial impact of producing Cryo AHF and IFC from a blood center’s perspective.

Study

Design/Methods: An Excel model was built and populated with base case costs and workflow assumptions identified through a time/motion study and literature search. The model allows base-case assumptions to be overwritten with values specific to the institution. Annual costs for Cryo AHF and IFC production, including labor, QC testing, and kits/pooling sets, were compared for 4 scenarios, each representing a different production mix: 100% pooled Cryo AHF, 100% IFC, 50/50% Cryo AHF/IFC, and 70%/30% Cryo AHF/IFC.


Model Assumptions


  • Blood center collects 20,000 units of WBD plasma

  • IFC and Cryo AHF derived from 4 and 5 WBD plasma units, respectively

  • An IFC 4-pool product provides approximately 1.5g of fibrinogen, comparable to the lower range of average fibrinogen content in a Cryo AHF 5-pool

  • Pricing to hospital:


Pooled Cryo AHF: $375/unit

Cryo-poor plasma from Cryo AHF: $50/unit

IFC: $925/unit





Results/Findings: The financial impact based on each of the four production-mix scenarios are shown below.

Conclusions: Though the model predicts increased production costs for IFC compared to Cryo AHF, blood centers may achieve greater revenue with IFC. This is largely because less WBD plasma is required for IFC (4-pool) vs. Cryo AHF (5-pool) leading to greater product availability. In addition, IFC provides benefits to hospitals and patients such as longer post-thaw shelf-life, faster time to issue when stored thawed, and reduced waste when compared to Cryo AHF.